BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35921896)

  • 1. The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface.
    Kremer PG; Barb AW
    J Biol Chem; 2022 Sep; 298(9):102329. PubMed ID: 35921896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antibody-binding Fc gamma receptor IIIa / CD16a is N-glycosylated with high occupancy at all five sites.
    Lampros EA; Kremer PG; Aguilar Díaz de León JS; Roberts ET; Rodriguez Benavente MC; Amster IJ; Barb AW
    Curr Res Immunol; 2022; 3():128-135. PubMed ID: 35712026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody Fucosylation Lowers the FcγRIIIa/CD16a Affinity by Limiting the Conformations Sampled by the N162-Glycan.
    Falconer DJ; Subedi GP; Marcella AM; Barb AW
    ACS Chem Biol; 2018 Aug; 13(8):2179-2189. PubMed ID: 30016589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restricted processing of CD16a/Fc γ receptor IIIa
    Patel KR; Roberts JT; Subedi GP; Barb AW
    J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-specific N-glycan Analysis of Antibody-binding Fc γ Receptors from Primary Human Monocytes.
    Roberts JT; Patel KR; Barb AW
    Mol Cell Proteomics; 2020 Feb; 19(2):362-374. PubMed ID: 31888963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allotype-specific processing of the CD16a N45-glycan from primary human natural killer cells and monocytes.
    Patel KR; Roberts JT; Barb AW
    Glycobiology; 2020 Jul; 30(7):427-432. PubMed ID: 31967297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single amino acid distorts the Fc γ receptor IIIb/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a.
    Roberts JT; Barb AW
    J Biol Chem; 2018 Dec; 293(51):19899-19908. PubMed ID: 30361439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD16a with oligomannose-type
    Subedi GP; Barb AW
    J Biol Chem; 2018 Oct; 293(43):16842-16850. PubMed ID: 30213862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Human Natural Killer Cells Retain Proinflammatory IgG1 at the Cell Surface and Express CD16a Glycoforms with Donor-dependent Variability.
    Patel KR; Nott JD; Barb AW
    Mol Cell Proteomics; 2019 Nov; 18(11):2178-2190. PubMed ID: 31467031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor.
    Subedi GP; Barb AW
    MAbs; 2016; 8(8):1512-1524. PubMed ID: 27492264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fc γ receptor IIIa/CD16a processing correlates with the expression of glycan-related genes in human natural killer cells.
    Patel KR; Rodriguez Benavente MC; Lorenz WW; Mace EM; Barb AW
    J Biol Chem; 2021; 296():100183. PubMed ID: 33310702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering of the upper hinge region of human IgG1 Fc enhances the binding affinity to FcγIIIa (CD16a) receptor isoform.
    Ashoor DN; Ben Khalaf N; Bourguiba-Hachemi S; Marzouq MH; Fathallah MD
    Protein Eng Des Sel; 2018 Jun; 31(6):205-212. PubMed ID: 30299461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of high-affinity anti-CD16A allotype-independent human antibody domains.
    Li W; Yang H; Dimitrov DS
    Exp Mol Pathol; 2016 Oct; 101(2):281-289. PubMed ID: 27712994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site-Specific Glycosylation Analysis of Murine and Human Fcγ Receptors Reveals High Heterogeneity at Conserved
    Pavan CH; Abdoollah Z; Marrero Roche DE; Ryan HR; Moore E; Chandler KB
    J Proteome Res; 2024 Mar; 23(3):1088-1101. PubMed ID: 38363599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
    Rodriguez Benavente MC; Hughes HB; Kremer PG; Subedi GP; Barb AW
    Immunology; 2023 Oct; 170(2):202-213. PubMed ID: 37218360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry.
    Woodall DW; Dillon TM; Kalenian K; Padaki R; Kuhns S; Semin DJ; Bondarenko PV
    MAbs; 2022; 14(1):2004982. PubMed ID: 34978527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbohydrate-Polypeptide Contacts in the Antibody Receptor CD16A Identified through Solution NMR Spectroscopy.
    Subedi GP; Falconer DJ; Barb AW
    Biochemistry; 2017 Jun; 56(25):3174-3177. PubMed ID: 28613884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of N-Glycan Composition on Structure and Dynamics of IgG1 Fc and Their Implications for Antibody Engineering.
    Lee HS; Im W
    Sci Rep; 2017 Oct; 7(1):12659. PubMed ID: 28978918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycosylation of Fcγ receptors influences their interaction with various IgG1 glycoforms.
    Cambay F; Forest-Nault C; Dumoulin L; Seguin A; Henry O; Durocher Y; De Crescenzo G
    Mol Immunol; 2020 May; 121():144-158. PubMed ID: 32222585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Fc Gamma Receptor Glycoforms That Produce Differential Binding Kinetics for Rituximab.
    Hayes JM; Frostell A; Karlsson R; Müller S; Martín SM; Pauers M; Reuss F; Cosgrave EF; Anneren C; Davey GP; Rudd PM
    Mol Cell Proteomics; 2017 Oct; 16(10):1770-1788. PubMed ID: 28576848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.